Intra-cellular Therapies, Inc.

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during a sudden worsening of psychosis. 335 adults with schizophrenia took either the study drug, a placebo, or an active control for 28 days. The main goal was to see if ITI-007 improves sym…

This study looked at whether adding lumateperone to standard antidepressants is safe for people with major depressive disorder. Over 800 adults who completed earlier studies took the drug for 26 weeks. The main goal was to track side effects, and researchers also measured changes…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia better than a placebo. About 450 adults with an acute episode of psychosis took either the drug or a placebo for 28 days. The main goal was to see if their symptoms improved, as measured by a…